Clinical and laboratory double-blind investigation on effect of fibrinolytic therapy in patients with cutaneous vasculitis.
The effects of phenformin and ethyloestrenol and phenformin and stanozolol on the clinical state, plasma fibrinolytic activity, and fibrinogen-fibrin-related antigen (F.R.-antigen) were compared with placebo in 13 patients with cutaneous vasculitis. Eight patients showed considerable clinical improvement when taking phenformin and an anabolic steroid; an impaired fibrinolytic activity before treatment favoured clinical improvement.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000941:Antigens; D001780:Blood Coagulation Tests; D002986:Clinical Trials as Topic; D005032:Ethylestrenol / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005337:Fibrin; D005340:Fibrinogen; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000494:pharmacology / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*; D013197:Stanozolol / Q000494:pharmacology / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000188:drug therapy*
D000941:Antigens; D013197:Stanozolol; D005337:Fibrin; D005340:Fibrinogen; D005032:Ethylestrenol; D010629:Phenformin